Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-12-27
DOI
10.1007/s00259-021-05650-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy
- (2021) E. Ghisoni et al. EUROPEAN JOURNAL OF CANCER
- Image intensity histograms as imaging biomarkers: application to immune-related colitis.
- (2021) Daniel T Huff et al. Biomedical Physics & Engineering Express
- Immune checkpoint inhibitor related adverse effects and FDG PET/CT findings
- (2021) Jan-Henning Schierz et al. Journal of Nuclear Medicine Technology
- Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials
- (2020) D.E. Magee et al. ANNALS OF ONCOLOGY
- Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer
- (2020) Charles Dolladille et al. JAMA Oncology
- The value of 18F-FDG PET/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis
- (2020) Narjess Ayati et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Increased thyroid uptake on 18F-FDG PET/CT is associated with the development of permanent hypothyroidism in stage IV melanoma patients treated with anti-PD-1 antibodies
- (2020) Alexandra Frelau et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
- (2019) O Hamid et al. ANNALS OF ONCOLOGY
- Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT
- (2019) Tomomi Nobashi et al. CLINICAL NUCLEAR MEDICINE
- Combo loss: Handling input and output imbalance in multi-organ segmentation
- (2019) Saeid Asgari Taghanaki et al. COMPUTERIZED MEDICAL IMAGING AND GRAPHICS
- Clinical significance of signs of autoimmune colitis in 18F-fluorodeoxyglucose positron emission tomography-computed tomography of 100 stage-IV melanoma patients
- (2019) Nina Lang et al. Immunotherapy
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
- (2019) Caroline Robert et al. LANCET ONCOLOGY
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes
- (2019) Aanika Balaji et al. Journal of Oncology Practice
- Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1
- (2018) Ahmed Mekki et al. EUROPEAN JOURNAL OF CANCER
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma
- (2018) A C Tan et al. ANNALS OF ONCOLOGY
- Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PET–CT
- (2018) Antonia Dimitrakopoulou-Strauss CANCER IMMUNOLOGY IMMUNOTHERAPY
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- FDG PET/CT for assessing tumour response to immunotherapy
- (2018) Nicolas Aide et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Dual-modality multi-atlas segmentation of torso organs from [18F]FDG-PET/CT images
- (2018) Hongkai Wang et al. International Journal of Computer Assisted Radiology and Surgery
- Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy
- (2018) Paolo A. Ascierto et al. JAMA Oncology
- Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18 F-FDG PET/CT Imaging in Patients with Advanced Melanoma
- (2017) Steve Y. Cho et al. JOURNAL OF NUCLEAR MEDICINE
- Efficient multi-scale 3D CNN with fully connected CRF for accurate brain lesion segmentation
- (2017) Konstantinos Kamnitsas et al. MEDICAL IMAGE ANALYSIS
- Management of toxicities of immune checkpoint inhibitors
- (2016) Lavinia Spain et al. CANCER TREATMENT REVIEWS
- Cloud-Based Evaluation of Anatomical Structure Segmentation and Landmark Detection Algorithms: VISCERAL Anatomy Benchmarks
- (2016) Oscar Jimenez-del-Toro et al. IEEE TRANSACTIONS ON MEDICAL IMAGING
- 3D Slicer as an image computing platform for the Quantitative Imaging Network
- (2012) Andriy Fedorov et al. MAGNETIC RESONANCE IMAGING
- LabKey Server: An open source platform for scientific data integration, analysis and collaboration
- (2011) Elizabeth K Nelson et al. BMC BIOINFORMATICS
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Meta-analysis of the performance of 18F-FDG PET in cutaneous melanoma
- (2009) Felisa Jiménez-Requena et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Comparison and Evaluation of Methods for Liver Segmentation From CT Datasets
- (2009) T. Heimann et al. IEEE TRANSACTIONS ON MEDICAL IMAGING
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started